Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
On Thursday, Raymond (NSE:RYMD) James provided insights into the current trends in healthcare provider (HCP) engagement, as observed through Veeva Systems (NYSE:VEEV) Inc’s first-quarter Pulse Field Trends report. The report, which reflects Veeva’s extensive reach in serving over 80% of pharmaceutical customer relationship management (CRM) sales representatives, did not update the access metric to HCPs this quarter. However, it did reveal current statistics on channel mix and email engagement rates, which are crucial for the vertical healthcare coverage. According to InvestingPro data, Doximity ’s strong market position is reflected in its impressive 90.2% gross profit margins and robust revenue growth of nearly 20% over the last twelve months.
In-person interactions continue to dominate as the primary mode of engagement with HCPs, accounting for 78% of total meetings. Email ranks second, representing 17% of the total mix. Notably, while email volume has increased significantly, open rates globally have decreased by 2%, with a sharper 5% decline in the U.S. This pattern indicates a need for life sciences organizations to further invest in innovative sales and marketing channels and to focus on campaign attribution and analytics to maintain efficient and effective HCP access—a positive development for both Veeva Systems and Doximity Inc (NYSE:DOCS). InvestingPro analysis reveals Doximity’s strong financial position, with a current ratio of 6.97 and minimal debt, positioning it well for continued investment in digital innovation. For detailed insights into Doximity’s growth potential and 13 additional ProTips, investors can access the comprehensive Pro Research Report.
The Pulse report also highlighted potential efficiency gains from artificial intelligence (AI) in content creation for HCP engagement. It suggested that AI could speed up production by over 20% and cut content costs by 30-50%. This information is particularly relevant for Veeva, which aims to utilize its pharma expertise to develop targeted functionalities in the application layer, including automating Medical (TASE:BLWV), Legal, and Regulatory (MLR) approval processes.
These advancements are also significant for Doximity, as the company seeks to use AI to improve HCP-targeted content creation for large pharmaceutical firms. Such developments could potentially accelerate the deployment of campaigns with Doximity, which already boasts an impressive EBITDA margin in the mid-50s percentage range. The efficiency in content creation could also lead to increased investments in other business areas, especially research and development (R&D).
In other recent news, Doximity Inc. reported strong fourth-quarter earnings for fiscal year 2025, surpassing Wall Street expectations with an earnings per share (EPS) of $0.38, compared to the forecasted $0.27. The company achieved a revenue of $138.3 million, exceeding the anticipated $134.03 million, marking a 17% year-over-year increase. Despite these positive results, Doximity’s stock experienced a sharp decline in aftermarket trading. Truist Securities adjusted its price target for Doximity from $58 to $52, maintaining a Hold rating, citing cautious fiscal year 2026 guidance due to macroeconomic uncertainties. Raymond James also revised its price target from $83 to $65, continuing to recommend the stock with an Outperform rating, highlighting robust backlog growth and potential revenue generation from AI investments. Evercore ISI lowered its price target to $50, noting strong growth in new products but expressing caution due to potential policy uncertainties affecting the pharmaceutical sector. Goldman Sachs reduced Doximity’s stock price target to $50, maintaining a Neutral rating, and projected a stabilization in revenue growth rate through fiscal year 2029.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.